Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories
20.3.2023 09:43:28 CET | news aktuell GmbH | Press release
- Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment
- Agreement includes further product development activities for Clinigen Limited
- Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally
(Munich / London / Athens) – Munich-based pharmaceutical contract development organization (CDMO) Adragos Pharma GmbH has signed a definitive agreement with global pharmaceutical services company Clinigen Limitedto acquire Lamda Laboratories S.A. in Athens. The acquisition of Lamda Laboratories significantly expands Adragos' pharmaceutical product development, regulatory affairs and supply chain management services for its global pharmaceutical customers.
Lamda has not only acted as Clinigen’s sole development center but has also established a well-earned reputation as a highly reliable contract development organization (CDO) for third party customers. Under a pharmaceutical development services agreement, Lamda will continue to provide services for Clinigen Limited.
The Athens site, a mere 15 minute drive from the airport, is fully equipped with state of the art equipment including the handling of potent drugs, established Quality systems and a proven track record of delivering complex developments on time for customers.
A highly experienced management team and well-trained staff will continue to focus on complex product development for growing markets in Europe, Japan, and North America. Lamda will offer an expanded range of pharmaceutical development, regulatory affairs and supply chain management services for a wide range of dosage forms including complex and high potent oral solids, differentiated oral liquids, injectables and topical medicines. As part of the transaction, Adragos secures royalty streams for products stemming from previous co-developments.
David Bryant, Interim CEO of Clinigen Limited states: "We are pleased to have found in Adragos Pharma a trusted partner to build on the success story of Lamda with its great team taking it to the next level while also continuing to support Clinigen as we focus on providing high-value services to the biopharma industry.”
Dr. Andreas Raabe, CEO of Adragos Pharma commended the “impressive track record and professional service mindset at Lamda”. He noted that “Lamda combines differentiated product development capabilities with substantial scale, an essential combination for our international group.”
The exact terms of the transaction will not be disclosed. Completion of the transaction is subject to customary conditions precedent.
About Adragos
Adragos Pharma is a globally operating CDMO with headquarters in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan to attain a globally leading position within the next few years and set new standards in customer service and data centricity. In its buy-and-build growth strategy, Adragos Pharma is supported by FSN Capital, a leading Northern European private equity firm, and Prange Group, a diversified leading German family office. Adragos Pharma currently operates four production sites in France, Germany, and Japan.www.adragos-pharma.com
About Clinigen
Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa and the Asia Pacific. Clinigen has more than 1,000 employees across five continents in 15 countries, and provides access in more than 120 countries every year. For more information on Clinigen, please visit: www.clinigengroup.com
Contacts
Press contact Adragos Pharma
press@adragos-pharma.comAbout news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Neato expands exchange programme for customers across Europe19.11.2026 13:35:39 CET | Press release
Wuppertal, 19 November 2026 – Neato Robotics is significantly expanding its exchange programme for Neato customers across Europe, with the support of the Vorwerk Group. The programme is available to eligible private customers who purchased a Neato robot after 1 October 2020.
Advanced Robotics Conference 2026: FEV highlights pathways to industrial deployment of Physical AI19.11.2026 11:00:00 CET | Press release
Aachen, Germany, November 2026 – The Advanced Robotics Conference (ARC) 2026 will bring together leading representatives from international technology companies, start-ups, and research institutions at FEV’s headquarters in Aachen, Germany, on November 25 and 26. The event will focus on the latest technological developments, specific fields of application, and the prerequisites for the widespread adoption of advanced robotics.
Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored17.11.2026 16:00:00 CET | Press release
Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp honored for groundbreaking research on metabolic diseases and obesity therapies. Minister-President Boris Rhein presents the medical award, endowed with a total of one million euros, at the Hessian State Chancellery. Titia große Broermann: " this year’s laureates powerfully demonstrate how scientific curiosity sparks medical progress that can transform millions of lives”
PARACELSUS MEDICAL UNIVERSITY: PHARMACY PROGRAM GOES INTERNATIONAL16.11.2026 09:00:00 CET | Press release
Starting in the fall of 2027, the “Pharmacy and Pharmaceutical Sciences” program will be the first English-taught pharmacy program in the German-speaking region to qualify students to work across a range of pharmacy roles and settings.
Infomaniak and Gruyère Energie develop a data center project in Bulle designed to limit its footprint13.11.2026 13:41:04 CET | Press release
Geneva and Bulle, 13 November 2026 – Infomaniak SA (SIX: INFO), a Swiss cloud provider, and Gruyère Energie SA announce that the planning application for a data center in Bulle will be put on public display on 13 November. Planned for 2028, this next-generation facility is intended to meet growing digital needs while reusing the heat produced by its servers in the existing district heating network. Its planned IT capacity of 2.5 megawatts (MW) is twice that of Infomaniak’s most recent data center, in Geneva. The project remains modest in size.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
